{"type":"trials","record":{"id":42198,"source_id":"clinicaltrials-gov","external_id":"NCT04241536","title":"Metabolomics: A Novel Tool for Investigating the Pathogenesis of Age-related Macular Degeneration","brief_summary":"The global aim of this project is to expand the knowledge on the multifactorial pathogenesis of AMD. In addition to age, the multifactorial pathogenesis of AMD includes environmental and genetic risk factors. However, how these interact to promote progression remains largely unknown. AMD is a progressive retinal disease characterized by mostly asymptomatic early phases and progression to potentially blinding late forms (choroidal neovascularization or geographic atrophy). Individuals vary in their rate of progression, with some remaining stable for years. The reasons behind this variability, as well as the triggers and mechanisms of AMD progression, are not well understood. Currently, the standard of care for assessment of the risk of progression is solely based on fundus appearance, and is limited in its prediction ability. Our previous work showed that metabolomics enables the identification of specific plasma metabolomic profiles in AMD, which vary with the severity stages. The investigators hypothesize that the plasma and urinary metabolomic profile of subjects who progress over a five-year period (progressors) is distinct from those who remain at the same AMD severity stage (non-progressors). In this proposal, the investigators will follow our existing cohort over five years, comparing the metabolomic profiles of progressors to non-progressors.","overall_status":"Completed","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Association for Innovation and Biomedical Research on Light and Image","enrollment":295,"countries":["Portugal"],"start_date":"2021-06-01","completion_date":"2022-11-29","last_update_date":"2023-01-09","source_url":"https://clinicaltrials.gov/study/NCT04241536","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"AMDMetab","age_range":"55 Years","comparator":null,"organization":"Association for Innovation and Biomedical Research on Light and Image","interventions":["Blood draw and urine collection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["comparison of the metabolomic profile of AMD-progressors and non-progressors — 1 year","define statistically relevant metabolite changes with potential value as biomarkers of AMD progression — 1 year"],"design_description":"NA · SINGLE GROUP · OTHER · NONE","source_has_results":false},"controlled_terms":["Age-related Macular Degeneration","Blood draw and urine collection"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04241536","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2021-06-01 to 2022-11-29","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.934Z","intervention":["Blood draw and urine collection"],"participants":295,"study_design":"NA · SINGLE GROUP · OTHER · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["comparison of the metabolomic profile of AMD-progressors and non-progressors — 1 year","define statistically relevant metabolite changes with potential value as biomarkers of AMD progression — 1 year"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42198","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}